Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

Benzinga Newsdesk www.benzinga.com Positive 52.9%

Neg 0% Neu 0% Pos 52.9%

Needham analyst Ami Fadia initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $68.